Harrow, Inc. (HROW) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Harrow, Inc. on August 3, 2026. The filing discloses the entry into a Material Definitive Agreement with Viatris Inc. to acquire global rights to TYRVAYA® (varenicline solution) nasal spray, a treatment for dry eye disease.
Key Financial Metrics and Transaction Terms
The filing details a specific acquisition transaction rather than periodic financial performance metrics. Key financial terms include:
- Upfront Consideration: $30,000,000 in cash payable at closing.
- Contingent Consideration: Up to $70,000,000 in milestone payments based on achieving specified annual net sales thresholds.
- Total Potential Value: Up to $100,000,000.
- Funding Source: The Company expects to fund the upfront cash payment with cash on hand.
- Adjustments: The purchase price is subject to a customary post-closing adjustment based on net working capital.
The filing text does not provide current revenue, profit, cash flow, margins, debt, or liquidity figures for the Company.
Material Changes and Outlook
The primary material change is the strategic expansion into the dry eye disease market through the acquisition of TYRVAYA assets, including regulatory approvals, intellectual property, and inventory. The Company expects the transaction to close in the second half of 2026, subject to customary closing conditions. No specific financial guidance or outlook for the Company's existing operations is provided in this filing.
Risks and Contingencies
Management highlights several risks and contingencies:
- Closing Uncertainty: There is no assurance the Acquisition will be completed on the anticipated timeline or at all.
- Forward-Looking Statements: Actual results may differ materially from expectations regarding the timing of the deal, funding, and achievement of milestone payments.
- Realization of Benefits: The anticipated benefits of the Acquisition may not be realized.
Investor Verification Checklist
- Verify the Company's current cash on hand to confirm ability to fund the $30 million upfront payment.
- Review the full text of the Asset Purchase Agreement (to be filed as an exhibit to the Q3 2026 10-Q) for specific sales thresholds triggering the $70 million in milestones.
- Monitor the status of closing conditions to assess the likelihood of the transaction completing in the second half of 2026.
- Assess the impact of the acquisition on the Company's balance sheet and future cash flow requirements once the deal closes.